It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pathogenic variants in myosin heavy chain (Myh11) cause familial thoracic aortic aneurysms and dissections (FTAAD). However, the underlying pathological mechanisms remain unclear because of a lack of animal models. In this study, we established a mouse model with Myh11 K1256del, the pathogenic variant we found previously in two FTAAD families. The Myh11∆K/∆K aorta showed increased wall thickness and ultrastructural abnormalities, including weakened cell adhesion. Notably, the Myh11∆K/+ mice developed aortic dissections and intramural haematomas when stimulated with angiotensin II. Mechanistically, integrin subunit alpha2 (Itga2) was downregulated in the Myh11∆K/∆K aortas, and the smooth muscle cell lineage cells that differentiated from Myh11∆K/∆K induced pluripotent stem cells. The contractility of the Myh11∆K/∆K aortas in response to phenylephrine was also reduced. These results imply that the suboptimal cell adhesion indicated by Itga2 downregulation causes a defect in the contraction of the aorta. Consequently, the defective contraction may increase the haemodynamic stress underlying the aortic dissections.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Jichi Medical University, Division of Clinical Pharmacology, Department of Pharmacology, Tochigi, Japan (GRID:grid.410804.9) (ISNI:0000 0001 2309 0000); Jichi Medical University, Division of Cardiovascular Medicine, Department of Medicine, Tochigi, Japan (GRID:grid.410804.9) (ISNI:0000 0001 2309 0000)
2 Jichi Medical University, Division of Clinical Pharmacology, Department of Pharmacology, Tochigi, Japan (GRID:grid.410804.9) (ISNI:0000 0001 2309 0000)
3 Shinshu University Graduate School of Medicine, Department of Cardiovascular Research, Nagano, Japan (GRID:grid.263518.b) (ISNI:0000 0001 1507 4692)
4 University of Leicester Cardiovascular Research Centre, Glenfield Hospital, Department of Cardiovascular Sciences, Leicester, UK (GRID:grid.412925.9) (ISNI:0000 0004 0400 6581)
5 Gunma University Hospital, System Integration Center, Gunma, Japan (GRID:grid.411887.3) (ISNI:0000 0004 0595 7039)
6 The University of Tokyo, Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
7 RIKEN Center for Biosystems Dynamics Research, Kobe, Japan (GRID:grid.508743.d); RIKEN-JEOL Collaboration Center, Kobe, Japan (GRID:grid.7597.c) (ISNI:0000000094465255)
8 The University of Tokyo, Department of Cardiovascular Medicine, Graduate School of Medicine, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
9 Jichi Medical University, Division of Cardiovascular Medicine, Department of Medicine, Tochigi, Japan (GRID:grid.410804.9) (ISNI:0000 0001 2309 0000)
10 Jichi Medical University, Tochigi, Japan (GRID:grid.410804.9) (ISNI:0000 0001 2309 0000)